Company Overview of Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd. develops biological products through genetic engineering, cell culture technology, purification, and fill and finish technology. The company offers process development services, including cell line development programs, and upstream and downstream process development services, as well as develops, qualifies, and validates product-specific analytical methods. It also provides contract management services that comprise cGMP manufacturing programs for cell line development, process and analytical development, clinical phase I/II/III manufacturing, full-scale commercial manufacturing, and aseptic fill and finish operations. The company has a strategic alliance with Me...
Key Executives for Samsung Biologics Co., Ltd.
Chief Executive Officer, President and Director
Vice President of Corporate Business Operation Team
Chief Information Officer and Vice President
Executive Vice President and Director
Compensation as of Fiscal Year 2015.
Samsung Biologics Co., Ltd. Key Developments
Samsung Biologics Co., Ltd. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM
Jan 6 16
Samsung Biologics Co., Ltd. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Tae-Han Kim, Chief Executive Officer, President and Director.
Samsung Reportedly Considers Biotech Partners To Unload Shares
Dec 28 15
Samsung Electronics Co. Ltd. (KOSE:A005930) reportedly seeks sale of stakes in Samsung C&T Corp. (KOSE:A028260). Samsung Electronics is considering selling off Samsung C&T shares owned by Samsung SDI Co. Ltd. (KOSE:A006400) to its bio technology partners, possibly global pharmaceutical companies, The Herald Business reported on December 28, 2015. Citing the nation's antitrust rules that prohibit conglomerates from creating a new circular ownership through equity investments, the watchdog ordered Samsung SDI to unload 5 million or 2.6% shares in Samsung C&T by the March 1, 2016, deadline. Samsung Electronics said it would comply with the decision but could ask for a grace period to minimize the market impact. The report said the shares could be purchased by partners of Samsung C&T's pharmaceutical unit Samsung Biologics Co., Ltd. as part of Samsung Electronics's recent push into bio technology as its next growth engine. "Samsung Electronics could seek to unload not just the 2.6% shares but also all of Samsung C&T shares owned by other Samsung Electronics affiliates," a source was quoted as saying. "Several bidders have already expressed their intention to purchase,” a source said.
Samsung BioLogics to Construct Biopharmaceutical Manufacturing Plant
Dec 21 15
Samsung BioLogics celebrated the groundbreaking of its third plant in Incheon Free Economic Zone, Songdo, Korea. With a total investment of KRW 850 billion, the third plant will be a facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation. Once it begins operation, Samsung BioLogics expects to become the biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters. Once the third plant is in full operation, Samsung BioLogics expects it will be able to reach KRW 2 trillion in annual sales and KRW 1 trillion in operating profit. In the longer term, the company plans to continuously expand its CMO business with further investments planned for 4th and 5th plants. Samsung BioLogics' first plant has recently received official approval for production from the U.S. Food and Drug Administration, and its second plant is scheduled to begin operation in early 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 3, 2015